Clinical Trials
2 trialsNCT06699836 2026-05-18
CLOVER
CytoDyn, Inc.
Phase 2 Active not recruiting
NCT07536815 2026-04-27
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
CytoDyn, Inc.
Available